Home LATEST NEWS Human trials of an HIV vaccine using messenger RNA begin

Human trials of an HIV vaccine using messenger RNA begin


Despite four decades of research, scientists have still not succeeded in developing a vaccine against this disease which kills hundreds of thousands of people each year.

But recent successes in messenger RNA technology that have enabled the rapid development of COVID-19 vaccines, including Moderna’s, have raised hopes.

The aim of the vaccine tested is to stimulate the production of a certain type of antibody (bnAb), capable of acting against the very numerous variants of HIV in circulation, the virus causing the disease AIDS.

The vaccine seeks to educate B cells, which are part of our immune system, to produce these antibodies.

For this, the trial will test the injection of a first immunogen, that is to say of a substance capable of provoking an immune response, and of a booster immunogen injected afterwards.

They will be delivered via messenger RNA technology.

The production of bnAbs is widely considered a goal of HIV vaccination, and this is a first step in this process.the statement said.

Read:  Washington bans all transactions with the Russian central bank

Other immunogens will be needed to guide the immune system on [la bonne] pathway, but this combination of a boost and a boost could be the first key element of a possible HIV vaccine regimenestimated David Diemert, scientific manager of the test at one of the four sites where the latter is carried out, George Washington University.

The immunogens used were developed by the scientific research organization International AIDS Vaccine Initiative (IAVI) and the Scripps Research Institutewith support from the Bill & Melinda Gates Foundation, the US National Institute of Infectious Diseases (NIAD) and Moderna.

Last year, a first trial, which did not use messenger RNA, but tested the first immunogen, showed that the desired immune response was elicited in several dozen participants.

The next step was then to collaborate with Moderna.

Given the speed with which messenger RNA vaccines can be produced, this platform offers a more flexible and responsive approach to vaccine testing and designunderlines the press release.

Read:  Russian-Ukrainian talks resume today | War in Ukraine

The search for an HIV vaccine is long and difficult, and having new tools in terms of immunogens and platform could prove crucial to make rapid progress.estimated Mark Feinberg, boss of IAVI.

Previous articleSweden gives green light to burying nuclear waste for 100,000 years
Next articleDr. Boileau meets the press without François Legault | Coronavirus